Paediatric Cancer

The most common childhood cancers are cancers of the blood (leukaemias and lymphomas), brain, and central nervous system, accounting for over two thirds of the cancers diagnosed in children. Between 2014–2016, around 1,800 children were diagnosed with cancer each year in the UK. An additional 2,600 young people aged betweeen 15 and 24 are also diagnosed each year. Much research is directed at designing less toxic therapies, reducing therapeutic burden, and developing diagnostic tests to enhance patient stratification. This research is made possible in Cambridge by strong links between research labs and the clinic as well as contributions to international clinical trials.

Advancing research into children’s cancer and leukaemia across Cambridge

Programme Contacts

Cambridge University Hospitals NHS Foundation Trust
Programme Lead
University of Cambridge
Department of Pathology
Programme Lead
University of Cambridge
Department of Oncology
Programme Manager

Selected publications

Neuroblastoma

Neuroblastoma is a cancer of the peripheral nervous system and is largely diagnosed in children under the age of 5. On average, around 100 children will be diagnosed with neuroblastoma each year in the UK alone.

Research into this rare paediatric cancer in Cambridge is conducted in the labs of Prof. Anna Philpott and Dr Suzanne Turner. In the former lab, research is being conducted to elucidate the relationship between cellular proliferation and differentiation and how this finely controlled balance is affected in neuroblastoma. In the latter lab, the mechanisms of drug resistance of some neuroblastoma sub-types is being analysed. 

Funding: Neuroblastoma UK, CRUK, MRC

Latest publications

Trigg et al. Opportunities and challenges of circulating biomarkers in neuroblastoma. Open Biology 2019 May

Paediatric leukaemia and lymphoma

Research on paediatric leukaemia and lymphoma is conducted in the lab of Dr Suzanne Turner in close collaboration with clinical colleagues, namely by Dr Amos Burke.

Projects include characterising tumour heterogeneity in paediatric non-Hodgkin lymphoma (NHL), and investigating minimal residual (MRD) and minimal disseminated disease (MDD) as prognostic factors.

Research into paediatric leukaemias is analyzing mechanisms of therapy resistance and divulging novel therapeutic targets. This research is undertaken with close alignment to a portfolio of clinical trials conducted at both International and National levels. 

Latest publications

Special issue of BJH: Advances in Paediatric, Adolescent and Young Adult Lymphoma

Including: Santarsieri et al. A rare case of bone marrow infiltration by medulloblastoma in a child. Br J Haematol. 2019 Jun

Including: Larose et al From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK+. Br J Haematol. 2019 Jun

Junior Group Leader - Isaia Barbieri
Investigating the role of RNA modification in leukaemias and lymphomas, particularly METTL1, METTL3 and TGS1.
Left to right: Isaia Barbieri, Valentina Miano, Shi-Lu Luan, Annalaura Cocca

Latest publications

Pandolfini et al. METTL1 Promotes let-7 MicroRNA Processing via m7G Methylation. Mol Cell April 2019

ALKATRAS

ALK is increasingly recognised as a prevalent oncogene in a number of human malignancies, including anaplastic large cell lymphomas.
The European Training Network ALKATRAS (ALK as A target of TRAnslational Science) is supporting a cohort of 15 early stage researchers to become the next generation of cancer research specialists, several of whom are working in Suzanne Turner’s group in Cambridge.

Malignant germ cell tumours (GCTs)

Malignant germ cell tumours (GCTs) are complex cancers that affect patients of all ages. They develop from cells that produce eggs or sperm and mostly occur in the ovaries and testes. Around 2,500 men are diagnosed with testicular GCTs every year in the UK alone, and the disease is a leading cause of death of young men.

Dr Matthew MurrayDr James Nicholson and Prof Nick Coleman are leading research on the causes on GCTs, in particular in the investigation of the role of microRNAs; they were the first to show that increased levels of these microRNAs are present in the blood when malignant GCTs are diagnosed and that levels of the molecules can be monitored during treatment. In the future, microRNAs found in the blood are likely to be useful for improving the accuracy of diagnosis and disease-monitoring in other solid tumours of childhood.

Latest publications

Depani et al. Results from the UK Children's Cancer and Leukaemia Group study of extracranial germ cell tumours in children and adolescents (GCIII). Eur J Cancer. 2019 Jul 12;118:49-57 

Frazer et al. Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management Gynecol Oncol. 2019 Jun 5

Charytonowicz et al. Cost Analysis of Noninvasive Blood-Based MicroRNA Testing Versus CT Scans for Follow-up in Patients With Testicular Germ-Cell Tumors. Clin Genitourin Cancer. 2019 Mar 27

Latest collaborations

Dr Matt Murray is collaborating with Dr Raheleh Rahbari (Wellcome Sanger Institute) to investigate developmental origins of germ cell tumours

Greyhound Limb Sparing Surgery
Paediatric musculoskeletal cancers

Research on paediatric musculoskeletal cancers is conducted in the labs of Professor Matthew Allen and Dr Jane Dobson. They are interested in preclinical modelling, with a particular emphasis on paediatric cancers (such as osteosarcoma, rhabdomyosarcoma and Ewings sarcoma) and adult cancers that spread to bone (such as breast, prostate, renal and lung cancer). They use a combination of cell culture and preclinical animal models to explore the mechanisms through which these cancers grow in bone and then spread (metastasise) to other organs.

They also work with dogs and cats with naturally-occurring cancer to evaluate new therapies and work on strategies for prevention of metastasis. It is known that certain soft tissue sarcomas appear more frequent in specific breeds of dog, suggesting an underlying genetic influence, which they are exploring.

Ultimately, they seek to develop new approaches to diagnose, track and treat these cancers in both animals and humans.

Funding: Sarcoma UK